Should I Invest In GlaxoSmithKline Plc Now?

Can GlaxoSmithKline plc (LON: GSK) still deliver a decent investment return?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKlineWhen I last wrote about pharmaceutical giant GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) back in August, the shares were at 1382p. Today’s 1400p sees the price trading in the same area, but I can’t help thinking the trend still appears to point down.

The recent three-quarter results won’t help sentiment. On a constant-exchange-rate basis, revenue for the year so far is down 7%, operating profit is down 24% and earnings per share are down 28%. Predictions for a poor year’s trading are looking correct.

Is the valuation too rich?

GlaxoSmithKline’s forward P/E rating hovers just under 15 for 2015. Doesn’t sound too bad, does it? Yet, it looks rich compared to predictions of just 3% growth in earnings that year, and that after an estimated 17% earnings’ decline this year. In fact, earnings have been volatile over the last few years.

So let’s look at the dividend to justify the valuation. A 5.8% forward yield is enticing, but with adjusted earnings set to cover the payout just over once, to me it looks vulnerable. Maybe the firm’s record on cash generation underpins optimism:

Year to December

2009

2010

2011

2012

2013

Net cash from operations (£m)

7,841

6,797

6,250

4,375

7,222

Here we find encouragement. Naturally, both maintenance and growth capex compete with the dividend for the firm’s cash flow, but cash flow is the great strength that makes ‘defensives’ such as GlaxoSmithKline so worthy of investor confidence.

Dividend payments cost GlaxoSmithKline around £3,918 million last year. So, assuming that this year’s cash flow isn’t down there should be ample funds to service the dividend, which is why the directors run dividend cover so close to the wire.

Cash is king

It seems that dividend yield, backed by cash flow, is the dominant factor that justifies GlaxoSmithKline’s valuation at present. Investors place their faith in the firm’s ability to develop and market a new generation of blockbusting drugs that could reignite earnings growth down the line.

Let’s hope that confidence in the firm’s pipeline pays off. It wouldn’t surprise me if speculation drove GlaxoSmithKline’s share price artificially high in the wake of  Pfizer‘s pitch at AstraZeneca. If so, there could be downside risk if the next numbers on cash flow disappoint.

What also of the valuation-cycle effect that tends to push defensive-style companies around? The valuations of defensives can move counter to the wider economic cycle. Companies seen as defensive, with reliable income streams, are most appealing to investors in volatile economic times, and valuations can rise. In more benign economic times investors often head for exciting investments and the defensives can see their valuations contract.

What next?

We’ll find out more with the full-year results due around 5 February — I’ll be heading straight for the cash flow report.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »